-
1
-
-
84859393995
-
CTLA-4 blockade with ipilimumab: Long-term follow-up of 177 patients with metastatic melanoma
-
Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012;18:2039-47.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 2039-2047
-
-
Prieto, P.A.1
Yang, J.C.2
Sherry, R.M.3
Hughes, M.S.4
Kammula, U.S.5
White, D.E.6
-
2
-
-
0030300139
-
The role of CTLA-4 in the regulation and initiation of T-Cell responses
-
Chambers CA, Krummel MF, Boitel B, Hurwitz A, Sullivan TJ, Fournier S, et al. The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev 1996;153:27-46. (Pubitemid 27010762)
-
(1996)
Immunological Reviews
, Issue.153
, pp. 27-46
-
-
Chambers, C.A.1
Krummel, M.F.2
Boitel, B.3
Hurwitz, A.4
Sullivan, T.J.5
Fournier, S.6
Cassell, D.7
Brunner, M.8
Allison, J.P.9
-
3
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
-
(2010)
N Engl J Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
-
4
-
-
79959772576
-
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
-
Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
-
(2011)
N Engl J Med
, vol.364
, pp. 2517-2526
-
-
Robert, C.1
Thomas, L.2
Bondarenko, I.3
O'Day, S.4
Weber, J.5
Garbe, C.6
-
5
-
-
0033024863
-
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
-
Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16. (Pubitemid 29318842)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.7
, pp. 2105-2116
-
-
Atkins, M.B.1
Lotze, M.T.2
Dutcher, J.P.3
Fisher, R.I.4
Weiss, G.5
Margolin, K.6
Abrams, J.7
Sznol, M.8
Parkinson, D.9
Hawkins, M.10
Paradise, C.11
Kunkel, L.12
Rosenberg, S.A.13
-
6
-
-
0038153907
-
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
-
DOI 10.1073/pnas.1533209100
-
Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372-7. (Pubitemid 36842552)
-
(2003)
Proceedings of the National Academy of Sciences of the United States of America
, vol.100
, Issue.14
, pp. 8372-8377
-
-
Phan, G.Q.1
Yang, J.C.2
Sherry, R.M.3
Hwu, P.4
Topalian, S.L.5
Schwartzentruber, D.J.6
Restifo, N.P.7
Haworth, L.R.8
Seipp, C.A.9
Freezer, L.J.10
Morton, K.E.11
Mavroukakis, S.A.12
Duray, P.H.13
Steinberg, S.M.14
Allison, J.P.15
Davis, T.A.16
Rosenberg, S.A.17
-
7
-
-
27844458057
-
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study
-
DOI 10.1245/ASO.2005.03.536
-
Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005;12:1005-16. (Pubitemid 41660676)
-
(2005)
Annals of Surgical Oncology
, vol.12
, Issue.12
, pp. 1005-1016
-
-
Maker, A.V.1
Phan, G.Q.2
Attia, P.3
Yang, J.C.4
Sherry, R.M.5
Topalian, S.L.6
Kammula, U.S.7
Royal, R.E.8
Haworth, L.R.9
Levy, C.10
Kleiner, D.11
Mavroukakis, S.A.12
Yellin, M.13
Rosenberg, S.A.14
-
8
-
-
33747878218
-
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma
-
DOI 10.1097/01.cji.0000208259.73167.58, PII 0000237120060700000012
-
Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006;29:455-63. (Pubitemid 44288958)
-
(2006)
Journal of Immunotherapy
, vol.29
, Issue.4
, pp. 455-463
-
-
Maker, A.V.1
Yang, J.C.2
Sherry, R.M.3
Topalian, S.L.4
Kammula, U.S.5
Royal, R.E.6
Hughes, M.7
Yellin, M.J.8
Haworth, L.R.9
Levy, C.10
Allen, T.11
Mavroukakis, S.A.12
Attia, P.13
Rosenberg, S.A.14
-
9
-
-
73149092567
-
Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria
-
Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 7412-7420
-
-
Wolchok, J.D.1
Hoos, A.2
O'Day, S.3
Weber, J.S.4
Hamid, O.5
Lebbe, C.6
-
10
-
-
77950258677
-
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: Lymphocyte count after 2 doses correlates with survival
-
Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010;116:1767-75.
-
(2010)
Cancer
, vol.116
, pp. 1767-1775
-
-
Ku, G.Y.1
Yuan, J.2
Page, D.B.3
Schroeder, S.E.4
Panageas, K.S.5
Carvajal, R.D.6
-
11
-
-
78650439466
-
Ipilimumab efficacy and safety in patients with advanced melanoma: A retrospective analysis of HLA subtype from four trials
-
Wolchok JD, Weber JS, Hamid O, Lebbe C, Maio M, Schadendorf D, et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun 2010;10:9.
-
(2010)
Cancer Immun
, vol.10
, pp. 9
-
-
Wolchok, J.D.1
Weber, J.S.2
Hamid, O.3
Lebbe, C.4
Maio, M.5
Schadendorf, D.6
-
12
-
-
79960299888
-
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
-
Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-7.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 4550-4557
-
-
Rosenberg, S.A.1
Yang, J.C.2
Sherry, R.M.3
Kammula, U.S.4
Hughes, M.S.5
Phan, G.Q.6
|